Disease · HP_0002202

Pleural effusion

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Pleural effusion. Diseases, record HP_0002202. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002202

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Pleural effusion
Open Targets ID: HP_0002202
Other names: Fluid around lungs
Highest stage of its drugs: Approval, for 2 of its 21 drugs, from DailyMed

Source Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TALC	CHEMBL3989756	Small molecule	Approval	DailyMed	6	4	4	Drugs and targets
BLEOMYCIN SULFATE	CHEMBL6067493		Approval	DailyMed	2	0	0	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
ENDOSTATIN, N-TERMINAL-MGGSHHHHH	CHEMBL4297946		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
NITRIC OXIDE	CHEMBL1200689	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
TENECTEPLASE	CHEMBL2108791	Enzyme	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALTEPLASE	CHEMBL1201593	Enzyme	Phase 2	ClinicalTrials.gov	2	2	0	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets25

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PLAT	Tissue-type plasminogen activator	2	Tissue-type plasminogen activator exogenous protein	Phase 2/3	https://conductscience.org/library/genes/5327	Drugs and targets
ATP4A	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Phase 2	https://conductscience.org/library/genes/496	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 1	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor protein-tyrosine kinase erbB-2 inhibitor	Phase 1	https://conductscience.org/library/genes/2064	Drugs and targets
ERBB4	Receptor tyrosine-protein kinase erbB-4	1	Receptor protein-tyrosine kinase erbB-4 inhibitor	Phase 1	https://conductscience.org/library/genes/2066	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	1	Soluble guanylate cyclase activator	Phase 2/3	https://conductscience.org/library/genes/2982	Drugs and targets

1 to 10 of 25

See all 25 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01661790	Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer	Phase 3	72	2015-03-25	Malignant Pleural Effusion	BEVACIZUMAB, CISPLATIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00945529	The Effects of Inhaled Nitric Oxide After Fontan Operation	Phase 2/3	21	2023-05-19	Congenital Heart Defect	NITRIC OXIDE	Its record names the disease	ClinicalTrials.gov
NCT01580618	Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy	Phase 2/3	20	2015-01-06	Pleural Effusion	TENECTEPLASE	Its record names the disease	ClinicalTrials.gov
NCT04792970	Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion	Phase 4	4	2023-09-28	Malignant Pleural Effusion	TALC	Open Targets' reading of its record	ClinicalTrials.gov
NCT01327235	Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites	Phase 2	336		Malignant Pleural Effusion, Malignant Ascites	CISPLATIN, ENDOSTATIN, N-TERMINAL-MGGSHHHHH	Open Targets' reading of its record	ClinicalTrials.gov
NCT04914598	A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions	Phase 3	290		Malignant Pleural Effusion	CISPLATIN, ENDOSTATIN, N-TERMINAL-MGGSHHHHH	Open Targets' reading of its record	ClinicalTrials.gov
NCT06734481	Effectiveness and Safety of Sodium Bicarbonate Pleural Lavage in the Treatment of Complex Pleural Effusion	Not applicable	260		Complicated Pleural Effusion/ Empyema	SODIUM BICARBONATE	Its record names the disease	ClinicalTrials.gov
NCT03465774	Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions		208		Pleural Neoplasm	DOXYCYCLINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02054078	Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion	Phase 2	183		Malignant Pleural Effusion	BEVACIZUMAB, TALC	Open Targets' reading of its record	ClinicalTrials.gov
NCT06713382	Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]	Phase 2	96		Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bevacizumab & Cisplatin vs Cisplatin: serious adverse events	0 of 36	0 of 36	72	NCT01661790	Trial comparisons
Intervention vs No Intervention/ Historical Control Group: serious adverse events	5 of 21	8 of 23	44	NCT00945529	Trial comparisons
Normal Saline vs TNKase: serious adverse events	0 of 7	1 of 13	20	NCT01580618	Trial comparisons
Talc Instilled Via Tunneled Pleural Catheter Combined With Standard Daily Drainage vs Standard Daily Drainage: deaths from any cause	1 of 2	0 of 2	4	NCT04792970	Trial comparisons
Talc Instilled Via Tunneled Pleural Catheter Combined With Standard Daily Drainage vs Standard Daily Drainage: serious adverse events	1 of 2	1 of 2	4	NCT04792970	Trial comparisons

Papers from its trials24

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32367840	RESULT	1	PubMed
26449328	RESULT	1	PubMed
26075094	RESULT	1	PubMed
26022948	RESULT	1	PubMed
25798278	RESULT	1	PubMed
23925664	RESULT	1	PubMed
23178954	RESULT	1	PubMed
22083202	RESULT	1	PubMed
21633576	RESULT	1	PubMed
21267391	RESULT	1	PubMed

1 to 10 of 24

See all 24 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0002202

GET https://conductscience.org/api/diseases/v1/HP_0002202/drugs?page=2

API reference For AI assistants